Who
Rafael Bejar
Other role
Company insider
Files Form 4 as: Sr VP & Chief Medical Officer, Aptose Biosciences.
In numbers
- Trades disclosed
- 24
- Buys
- 1
- Sells
- 0
- Bought
- $26K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Jan 2020
- Last trade
- 30 Jun 2026
- Last filed
- 1 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 1 Jul 2026 | Aptose BiosciencesBiotechnology | SEC FORM 4 Code D | $420244 at $1.72 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —35,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —200,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —35,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —200,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —400,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —343,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —200,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —400,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —400,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —343,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —200,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —400,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciences | SEC FORM 4 Code D | $420244 at $1.72 | filing |
| 5 Feb 2024filed 7 Feb 2024 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 19 Jan 2023filed 23 Jan 2023 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 19 Jan 2023filed 23 Jan 2023 | Aptose Biosciences | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 18 Jan 2022filed 20 Jan 2022 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 19 Nov 2021filed 19 Nov 2021 | Aptose Biosciences | SEC FORM 4 Bought | $26K10,000 at $2.56 | filing |
| 19 Aug 2021filed 23 Aug 2021 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.